Roundtable
Roundtable
Advertisement
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
View More
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
David Morris, MD, FACSmHSPC | December 12, 2024
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
David Morris, MD, FACSmHSPC | December 12, 2024
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
David Morris, MD, FACSmHSPC | December 12, 2024
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
David Morris, MD, FACSCRPC | December 12, 2024
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
David Morris, MD, FACSmHSPC | December 12, 2024
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
David Morris, MD, FACSRoundtable | December 12, 2024
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
Gordon Brown, DONon-Muscle Invasive Urothelial Carcinoma | December 5, 2024
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
Katy Beckermann, MD, PhDRoundtable | November 21, 2024
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
Katy Beckermann, MD, PhDRoundtable | November 21, 2024
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Advertisement
Advertisement
Advertisement